EMEA-000876-PIP02-11-M01 - paediatric investigation plan
Eculizumab
PIPHuman
Alexion Europe SAS
France
E-mail: pip.enquiries.eu@alxn.com
Tel. +33 1 47 10 06 06
Fax +33 1 47 10 06 11
P/0306/2012: EMA decision of 21 December 2012 on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris) (EMEA-000876-PIP02-11-M01)